The stock will trade on CHAPTER-3 data timing (3Q2026) and NDA submission progress (1H2026). The $132M raise removes near-term dilution risk but signals capital needs. Monitor for any pre-announcement or regulatory updates on the NDA filing.
Price Chart
Executive Summary
Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a $132M offering into 2028. The key catalysts are the CHAPTER-3 Phase 3 HAE prophylaxis data due in 3Q2026 and the NDA submission for deucrictibant IR in 1H2026.
Key Financial Metrics
Key Facts
- Q1 2026 loss per share €-0.59 vs €-0.85 YoY (IFRS basis)
- Cash and equivalents €247M as of March 31, 2026, down from €292M at Dec 31, 2025
- Closed $132.3M underwritten offering post-quarter, extending cash runway into 2028
- CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q2026
- NDA submission for deucrictibant IR on track for 1H2026
- R&D expenses €29.9M (Q1 2026) vs €30.9M (Q1 2025); G&A €14.0M vs €11.3M
- No revenue reported; pre-revenue biotech
Financial Impact
No revenue; operating loss €43.9M (R&D + G&A) vs €42.2M YoY. Cash burn rate ~€45M/quarter, extended by $132M offering.
Risk Factors
- CHAPTER-3 Phase 3 failure would significantly impair pipeline value
- Regulatory delays or rejection of deucrictibant IR NDA
- Cash runway depends on no major cost overruns; further dilution possible if milestones slip
- Competition from existing HAE therapies (Takhzyro, Orladeyo, Kalbitor)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293384 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access